Corona Virus Infection, Covid19
Conditions
Keywords
COV-19, T cells, COV-2 PEPTIDE
Brief summary
The analysis method described in this protocol is a novel simple plausible immunological approach which is non-invasive, high throughput, real-time quantitative monitoring of metabolic activity (MA) profiles of fresh Peripheral Blood Mononuclear Cells (PBMC) in response to various reagents at different concentrations. The purpose of this study is to evaluate the T cells reactivity to SARS COV 2 immunogenic selected peptides by Metabolic Activity Method in convalesce and healthy individuals and to compare it with Antibody response (ELISA) and clinical information
Detailed description
This is a prospective, four groups, open, comparative, controlled study. A total of 400 completed, evaluated subjects will be enrolled in this study. Main Study Measures: Reactivity of T cells to selected SARS COV-2 peptides by MA test and IgG Antibody response to SARS COV-2 by commercial ELISA test. Study Procedures: * Screening * Informed consent signing * Medical history review * Blood collection. * MA test and ELISA test will be performed at Savicell's Laboratory site.
Interventions
DIAGNOSTIC_TESTSavicell's ImmunoBiopsy™
ImmunoBiopsy and ELISA
Sponsors
Savicell Diagnostics Ltd
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* All recruited subjects are between 18 to 90 years old. * All recruited subjects read the informed consent and then signed the informed consent. * All recruited subjects filled out the questionnaire form
Exclusion criteria
* Subject has active infection or inflammation determined clinically at screening. * Subject is currently treated with concomitant medication related directly or can affect the immune system as steroids. * Subject has impaired judgment. * Known positive HIV, hepatitis B, or hepatitis C, autoimmune disease. * Known history of a significant medical disorder, which in the investigators' judgment contraindicates the patient's participation. * Drug or alcohol abuse * Subject is participating in any other clinical trial for drug investigation within 10 days prior sample collection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Positive and negative diagnosis (scored 0/1 dichotomously) in accordance with test results (MA/ELISA/PCR) | week | T cells reactivity to SARS COV 2 immunogenic |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of positive for SARS - COV2 - in healthy donors. | week | Antibody response (ELISA) |
Countries
Israel
Contacts
Primary ContactYochai Adir, Prof
Outcome results
None listed